B+
Bull case
25%
Probability
Target price
$5.80
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
IMDX
Insight Molecular DiagnosticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A first-mover FDA authorization for a kitted dd-cfDNA transplant assay could shift IMDX from development story to commercial platform, with February financing reducing immediate balance-sheet stress and management highlighting growing transplant-center engagement [#10-K-2026-03-26] [#PR-2026-03-26].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.2.
What can break
Cash runway improved after the February 2026 raise, but losses remain heavy and future financing risk is not eliminated.
Momentum
7
Value
41
Sentiment
74
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.20 · Bull $5.80 · Bear $2.00Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $8.25
Why
Momentum7 · Δ7d +0.2
Value41 · Δ7d -0.0
Sentiment74 · Δ7d +8.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +8.2.
Contradictions & invalidation
- • Cash runway improved after the February 2026 raise, but losses remain heavy and future financing risk is not eliminated.
- • Commercial adoption claims are still early and not yet supported by meaningful product revenue.
- • The company remains essentially pre-revenue in its kitted product strategy, annual losses are still large, and the core upside depends on regulatory and commercialization milestones that are not yet de-risked; any FDA delay or slower uptake could quickly refocus investors on cash burn [#10-K-2026-03-26] [#PR-2026-03-26].
Catalyst clock
2026-06-30
Runway and loss-profile digestion after Q4/FY2025 results and February financing
Lead driver: Sentiment · See AI snapshot
Momentum
7
8% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-0.8
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
74
45% active weight
Current posture
7d trendImproving
Δ7d
+8.2
Δ21d
+16.8
Why this grade
Composite grade C. Momentum 7.4 / Value 40.6 / Sentiment 74.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-26
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$98.17M
Beta
1.35
Shares Out
32.72M
P/E (TTM) · Derived
-1.8
P/S (TTM)
48.64
P/FCF (TTM) · Derived
-3.32
Rev YoY
-53.9%
EPS YoY
+0.7%
Gross Margin
-93.4%
Op Margin
-2217.9%
Net Debt
-$8.82M
Current Ratio
2.00
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data